Medicine · Français

Will NCT06334133 (vTv Therapeutics) still show a study completion date of 31 May 2027 or earlier when checked on 30 June 2027?

deadline 2027-06-30 confidence medium tier 4 evidence
81%PolySignal estimate

Resolution criterion

Yes if, when NCT06334133 is read on clinicaltrials.gov on 30 June 2027, the exact API field protocolSection.statusModule.completionDateStruct.date — Study Completion Date is 31 May 2027 or earlier — that is, the date announced today has not been pushed back. A later recorded date counts as no. If OverallStatus is Terminated, Withdrawn, Suspended, or Unknown status, that counts as no — an unmaintained or halted record is treated as a failure to hold the date, not as a technicality. The value returned by the ClinicalTrials.gov API on the deadline prevails; where the record gives a month without a day, the last day of that month is used. If that exact field is absent or empty on an otherwise existing record, that also counts as no – a missing date is not evidence the deadline will be met, it is treated the same as a halted record.

Verified starting state

As of 6 October 2026: NCT06334133 is registered as ACTIVE_NOT_RECRUITING, sponsored by vTv Therapeutics, with 150 participants. Started 2024-06; announced primary completion 2027-04-30, announced study completion 2027-05-31 — announced to the month only. Record last updated 2026-07-28. The date under test is 2027-05-31. Source: clinicaltrials.gov/study/NCT06334133

What pushes it up

What pushes it down

What would move this number most

The primary uncertainty is whether the data collection for secondary endpoints or administrative close-out activities will extend beyond the current May 31, 2027, estimate.

How this number is built

Deadline2027-06-30
Base rate75%
Best evidencetier 4 · 1 article(s) used
Independent runs80 · 82 (spread 2 pts)
Confidencemedium
Evidence capnot triggered
Last revised2026-10-06 09:09
Modelgemini-3-flash-preview

Sources consulted

VTv Therapeutics Announces Completion of Enrollment in Phase 3 CATT1 Study of Cadisegliatin in Type 1 Diabetes (T1D)tier 4 · marketscreener.com · 2026-10-05